JP7690199B2 - Antiviral agents and antiviral processed products containing the same - Google Patents

Description

The present invention relates to an antiviral agent and an antiviral processed product containing the same.

Enveloped viruses such as influenza viruses and coronaviruses, as well as non-enveloped viruses such as noroviruses, cause various diseases, so compositions with antiviral properties have been developed to control these viruses. (Patent Document 1)

JP 2015-071752 A

The objective of the present invention is to provide an antiviral agent having excellent antiviral properties and an antiviral processed product containing the same.

Means for solving the problem

The present inventors have conducted extensive research to solve the above problems and have arrived at the present invention.
[1] An antiviral agent containing silver molybdate and zinc 2-ethylhexanoate.
[2] The above antiviral agent, wherein the content of silver molybdate is 5 to 25% by weight based on the total content of silver molybdate and zinc 2-ethylhexanoate.
[3] An antiviral processed product containing the above-mentioned antiviral agent.
[4] The antiviral product as described above, wherein the antiviral agent is blended in an amount of 0.1 to 10 parts by weight per 100 parts by weight of the antiviral product.
to provide.

The objective of the present invention is to provide an antiviral agent having excellent antiviral properties and an antiviral processed product containing the same.

The silver molybdate used in the antiviral agent of the present invention can be obtained, for example, by mixing an aqueous solution of a silver salt with an aqueous solution of a molybdate, subjecting the resulting precipitate to solid-liquid separation, and drying the resulting wet precipitate.
Examples of the silver salt include silver nitrate, silver acetate, silver sulfate, etc. Examples of the molybdate include sodium molybdate, potassium molybdate, ammonium molybdate, etc.

The zinc 2-ethylhexanoate used in the antiviral agent of the present invention can be obtained, for example, by double decomposition of zinc sulfate and ammonium caprylate. Zinc 2-ethylhexanoate sold by Fujifilm Wako Pure Chemical Industries, Ltd., etc. can also be used.

Since zinc 2-ethylhexanoate is a viscous liquid at room temperature, it may be used supported on a carrier with an oil absorption of 1.5 to 5.0 ml/g (measured according to JIS K5101-13-1). Examples of such carriers include calcium silicate and silicon dioxide having the above-mentioned oil absorption. Examples of calcium silicate include Fluorite (registered trademark) R and RT (manufactured by Tomita Pharmaceutical Co., Ltd.), and examples of silicon dioxide include Toxil (registered trademark) NR (Oriental Silicas Corporation). When used supported on a carrier, the amount of zinc 2-ethylhexanoate relative to the carrier (weight/weight) is usually four times or less.

The antiviral agent of the present invention preferably has a silver molybdate content in the range of 5 to 25% by weight relative to the total content of silver molybdate and zinc 2-ethylhexanoate.

The antiviral agent of the present invention may contain anti-discoloration agents, ultraviolet absorbers, etc., as necessary.

The antiviral agent of the present invention is blended into plastic agents such as resin films or sheets, coating agents such as paints and surface treatment agents, adhesives, fibers, paper, etc., and used as antiviral processed products. The antiviral agent of the present invention can exhibit excellent antiviral properties, particularly when blended into a resin component.

Examples of such resin components include alkyd resins, polyester resins, acrylic resins, urethane resins, epoxy resins, fluororesins, silicone resins, unsaturated polyester resins, melamine resins, phenolic resins, nitrocellulose resins, vinyl acetate resins, vinyl chloride resins, polyolefin resins, and acrylonitrile butadiene styrene resins.

The amount of the antiviral agent of the present invention to be added may vary depending on the material to be added, but is usually 0.1 to 10 parts by weight per 100 parts by weight of the antiviral processed product.

The antiviral processed products are used in materials related to the living environment, such as wall materials, handrails, floor materials, wooden floor materials, kitchen counters, furniture, and wallpaper; electrical product materials, such as the housings of refrigerators and air conditioners; textile products, such as filters; electrical product materials, such as protective films for the image displays of portable electronic devices; industrial product materials, such as seats and floor mats for automobiles and trains; and packaging materials, such as wrapping paper and cardboard. Each of these materials is suitably used as various materials with antiviral properties.

In the present invention, antiviral includes reducing infectivity by lowering the viral infectivity titer, inhibiting viral proliferation, and killing the virus.

The present invention will be specifically explained below with reference to formulation examples and test examples, but the present invention is not limited to these.

(Preparation of Silver Molybdate)
430.0 g of ion-exchanged water was placed in a 1 L glass beaker, 50.0 g of silver nitrate (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.) was added thereto, and the mixture was stirred and dissolved to prepare an aqueous silver nitrate solution. Also, 463.4 g of ion-exchanged water was placed in a 1 L separable round-bottom flask, 36.6 g of sodium molybdate dihydrate (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.) was added thereto, and the mixture was stirred and dissolved to prepare an aqueous sodium molybdate solution.

Next, silver molybdate was precipitated by dropping an aqueous silver nitrate solution into the aqueous sodium molybdate solution while stirring. The liquid containing silver molybdate obtained here was subjected to suction filtration, and the resulting residue was dried to obtain silver molybdate.

Formulation Example 1

1.0 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zinc octylate purity 99%) was mixed with 0.25 g of Fluorite RT, and then 0.25 g of the silver molybdate prepared above was added to obtain an antiviral agent (hereinafter referred to as formulation-1).

Formulation Example 2

1.125 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zinc octylate purity 99%) was mixed with 0.281 g of Fluorite RT, and then 0.125 g of the silver molybdate prepared above was added to obtain an antiviral agent (hereinafter referred to as formulation-2).

Comparative formulation example

0.25 g of the silver molybdate prepared above was used as a comparative preparation (hereinafter referred to as Comparative Preparation-1).
In addition, 1.0 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., zinc octylate purity 99%) was used as a comparative preparation (hereinafter referred to as comparative preparation-2).

<Preparation of test pieces of antiviral resin molding>
100 g of ZEST-1300 (polyvinyl chloride, manufactured by Shin-Daiichi Vinyl) was mixed with 45 g of diisononyl phthalate, 6.2 g of epoxidized soybean oil, and 12.3 g of a stabilizer for vinyl chloride resin LBK-793K (manufactured by Sakai Chemical Industry Co., Ltd.), and then kneaded at 170°C using a Labo Plastomill to obtain a vinyl chloride sol. 100 g of the vinyl chloride sol was kneaded with the formulation-1 to obtain a resin compound. The resin compound was pressed for 3 minutes using a press molding machine heated to 180°C, and then cooled to room temperature to obtain a polyvinyl chloride sheet having a thickness of 0.5 mm, and the sheet was cut into 5 cm x 5 cm to obtain a test piece. Two test pieces were prepared.

(Antiviral test against influenza virus)
In accordance with ISO21702, influenza virus H3N2 strain (influenza A virus: A/Hong Kong/8/68: TC adapted ATCC VR-1679) was cultured in MDCK cells (canine kidney-derived cells) to obtain a test influenza virus suspension with a virus infectivity of 2 x 10 ⁷ Plaque Forming Unit/ml (hereinafter referred to as PFU/ml).

One of the test pieces was placed in a plastic petri dish, 0.4 ml of the above-mentioned test influenza virus suspension was dropped approximately in the center of the test piece, and then a 4 cm square polyethylene film was placed so as to cover the entire test virus suspension, and the test piece was stored at 25°C and 95% humidity for 24 hours. The test influenza virus suspension between the test piece and the polyethylene film was then washed out with 10 ml of SCDLP medium (Nihon Seiyaku), and the washed out solution was diluted 10-fold, 100-fold, 1000-fold, 10000-fold, and 100000-fold with EMEM medium, and the influenza virus infectivity (IV infectivity logarithm value) was measured on MDCK cells using the plaque assay method.

(Antiviral test against feline calicivirus)
According to ISO21702, feline calicivirus, strain F-9 (ATCC VR-782) was cultured in CRFK cells (cells derived from feline kidney) to obtain a test feline calicivirus suspension with a virus infectivity of 2×10 ⁷ Plaque Forming Unit/ml (hereinafter referred to as PFU/ml).

One of the test pieces prepared above was placed in a plastic petri dish, 0.4 ml of the above-mentioned test feline calicivirus suspension was dropped in the approximate center of the test piece, and then a 4 cm square polyethylene film was placed so as to cover the entire test virus suspension, and the test piece was stored at 25°C and 95% humidity for 24 hours. Next, the test feline calicivirus suspension between the test piece and the polyethylene film was washed out with 10 ml of SCDLP medium (Nihon Seiyaku), and this washed-out solution was diluted 10 times, 100 times, 1000 times, 10,000 times, and 100,000 times with EMEM medium (Fujifilm Wako Pure Chemical Industries, Ltd.), and the feline calicivirus infectivity (FCV infectivity logarithm value) was measured on CRFK cells by the plaque measurement method.

Two test pieces were prepared for each of formulation-2, comparative formulation-1, and comparative formulation-2 in the same manner as above, and antiviral tests against influenza virus and feline calicivirus were conducted in the same manner as the above test.

The test results are summarized in Table 1.

[Table 1]
Virus infectivity measurement results

Claims (4)

An antiviral agent containing silver molybdate and zinc 2-ethylhexanoate. The antiviral agent according to claim 1, characterized in that the content of silver molybdate relative to the total content of silver molybdate and zinc 2-ethylhexanoate is 5 to 25% by weight. An antiviral processed product containing the antiviral agent according to claim 1 or claim 2. The antiviral product according to claim 3, wherein the antiviral agent according to claim 1 or 2 is blended in an amount of 0.1 to 10 parts by weight per 100 parts by weight of the antiviral product.